Innoviva, Inc. (INVA) Stock Price & Analysis

Innoviva, Inc. (INVA) fell 0.09% to USD 21.33 as of September 8, 2026 at 05:42 UTC, according to Nexqual real-time market data.

INVA last closed at USD 21.35; the session ranged USD 21.09–21.36 on volume of 563,508 shares. Market capitalization is $1.54B, with a 52-week range of USD 16.52–25.15 (NMS). Source: Nexqual, September 8, 2026 at 05:42 UTC.

Key Statistics (as of September 8, 2026 at 05:42 UTC)

Technical Analysis (INVA)

Nexqual's technical model rates INVA "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 05:42 UTC.

Analyst Ratings (INVA)

Wall Street analysts rate INVA "None" based on 4 analysts, with a mean price target of USD 35 (range USD 18–46), per Nexqual as of September 8, 2026 at 05:42 UTC.

Earnings (INVA)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Financials & Fundamentals (INVA)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Financial Health Score (INVA)

Nexqual rates Innoviva, Inc.'s overall financial health "Strong" across five dimensions, as of September 8, 2026 at 05:42 UTC.

Ownership (INVA)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Leadership (INVA)

Innoviva, Inc. is led by Pavel Raifeld C.F.A. (age 41), CEO & Director, per Nexqual as of September 8, 2026 at 05:42 UTC.

Major Backers & Investors (INVA)

Notable institutional backers of Innoviva, Inc. include Renaissance Technologies, Millennium Management, Systematic Financial Management, L.P., according to Nexqual as of September 8, 2026 at 05:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

From Innoviva, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Despite the continued use of effective antibiotics, it remains one of the most common sexually transmitted bacterial infections in the world with an estimated 82 million people worldwide infected each year, including over 1 million people each year in the United States.
• During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application ("ANDA") or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval.
• On February 15, 2022, La Jolla received a paragraph IV notice of certification (the "Notice Letter") from Gland Pharma Limited ("Gland") advising that Gland had submitted an Abbreviated New Drug Application ("ANDA") to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA ® in the U.S. prior to the expiration of U.S.
• We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to GIAPREZA ® , XACDURO ® , XERAVA ® and NUZOLVENCE ® .

Partnerships

• Our distribution and license agreement with Basilea requires that the drug product is manufactured in accordance with the FDA's cGMPs and all other applicable laws and regulations.
• Our Integrated Critical Care / Infectious Disease Assets Commercial and Marketed Products Our critical care and infectious disease portfolio was formed through the 2022 acquisitions of Entasis Therapeutics and La Jolla Pharmaceutical, and we have continued to grow it through our license agreement with Basilea.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:42 UTC. This page is informational and not investment advice.